In pharmaceutical quality systems, long-term stability testing is critical to determine the shelf life and storage conditions of drug products. When deviations occur during these studies, the implications can be significant — potentially impacting regulatory filings, batch release, and product integrity. This case study offers insight into the structured approach taken by a pharmaceutical manufacturer when managing a temperature deviation during a 24-month stability study.
📅 Background: The Study Design
The case involves a generic oral solid dosage form undergoing ICH long-term stability testing at 25°C ± 2°C / 60% RH ± 5% RH. The study was conducted as part of a product registration dossier for the EU and US markets. The protocol included checkpoints at 0, 3, 6, 9, 12, 18, and 24 months.
Samples were stored in a qualified chamber connected to a validated data logger and alarm notification system. Each checkpoint required withdrawal of samples for testing on assay, dissolution, water content, and microbial limits.
⚠️ The Incident: Temperature Excursion
At the 18-month checkpoint, it was discovered that the chamber housing the samples had experienced a temperature excursion. The chamber logged temperatures between 28°C and 30°C for approximately 6 hours overnight, due to a chiller malfunction that went undetected until morning.
This prompted
🔎 Investigation and Root Cause Analysis
The deviation was formally logged, and a cross-functional team was assembled to investigate. The following steps were taken:
- Reviewed temperature and humidity logs
- Assessed alarm logs and alert notification records
- Interviewed shift supervisors and QA personnel
- Inspected HVAC and chiller maintenance records
- Tested alarm escalation system functionality
Root Cause: A faulty relay in the chiller unit failed to restart after a brief power surge, and the backup alarm failed to notify QA due to email system latency.
📝 Immediate Containment Measures
- Chamber isolated and samples tagged for excursion impact review
- Samples removed and transferred to validated backup chamber
- QA triggered internal notification to senior management
- Impact assessment initiated for 18-month checkpoint samples
Initial visual inspection showed no physical damage to samples. However, assay and dissolution tests were prioritized to detect any out-of-specification results.
✅ Data Review and Stability Risk Assessment
Laboratory testing of 18-month samples showed results within specification for assay, water content, and dissolution. Microbial limits were compliant. Historical trends (0M to 12M) showed no degradation trend.
A comparative review against control samples stored in another chamber at 25°C confirmed consistency.
Based on these findings, the deviation was considered to have negligible impact. Still, documentation had to support this decision robustly.
For guidance on deviation writing templates, refer to SOP training pharma.
📝 CAPA Plan Development
The QA department developed a formal Corrective and Preventive Action (CAPA) plan tied to the deviation. The actions included:
- Replacement of faulty chiller relay module
- Upgrade to dual-alarm notification system (SMS and email)
- Training for QA personnel on emergency response to equipment failure
- Validation of remote notification systems under simulated failure scenarios
- Review and update of deviation handling SOP
All CAPA actions were assigned owners and timelines, tracked in a centralized CAPA log, and followed up by QA during routine reviews.
📈 Regulatory Justification and Documentation
Given the stability samples were part of a product registration filing, the deviation and its resolution had to be clearly documented. The final stability report included:
- Deviation number and summary
- Details of temperature excursion with timestamp
- Results of sample testing before and after excursion
- Justification of data integrity based on risk assessment
- CAPA closure summary and effectiveness review
The format followed guidance from the ICH Q1A on stability testing and regional regulatory expectations from the USFDA.
🤓 Lessons Learned
- Stability chamber deviations are not always avoidable, but preparedness can reduce their impact.
- System redundancy — both for equipment and alert mechanisms — is critical.
- Clear documentation and scientifically justified impact assessments can preserve data validity.
- Training and simulation exercises for deviation handling strengthen QA systems.
These insights were incorporated into the facility’s annual quality risk management (QRM) review and shared across departments to raise awareness.
💻 Audit Readiness and Inspection Outcome
Six months after the incident, the site underwent a routine regulatory audit. The inspector reviewed deviation 22-STAB-036 related to the 18M chamber excursion. The following observations were noted in the inspection report:
- Root cause analysis was logical and supported by records
- CAPA actions were implemented and linked to change control
- Stability data remained reliable with no signs of degradation
- System upgrades (alarm notifications) were verified by inspector
No Form 483 was issued, and the case was cited as a good example of quality culture and proactive deviation management.
For related process validation and equipment qualification practices, explore process validation resources.
📰 Final Summary
This case study highlights the importance of systematic deviation and CAPA management within pharmaceutical stability programs. Even when data remains within specification, regulatory expectations require transparent documentation, root cause analysis, and robust preventive controls.
For pharma professionals, learning from real-world examples like these ensures better preparedness and a stronger quality management system.